Fenwick represented Journey Colab, a privately held psychedelic pharmaceutical startup, in its $12 million Series A financing. The Series A investors included MBX Capital, Delphi VC, Uprising, Lionheart Ventures, Sam Altman and Apollo Projects, and Drew Houston.
Journey Colab will use the funds to accelerate the development of its portfolio of psychedelic compounds being developed to treat addiction and other mental health disorders. More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partner Sam Angus and included associates Andrew Murphy, Joshua Fuller and Adam Conway.